Discussion of Phase 2 Bapineuzumab Data
A Panel Discussion among Six Neurologists
Price $2500
Deliverable: Discussion with key findings.
Study Description and Objectives:
To conduct a panel discussion among neurologists to discuss the preliminary results of the phase II clinical trial about bapineuzumab in Alzheimer’s disease. Secondary objectives:
§ To understand the current standard of care for Alzheimer’s patients
§ To evaluate the clinical effectiveness and safety of bapineuzumab based on the phase II trial information
§ To identify meaningful end points of the clinical trial
§ To evaluate the significance of the trial outcomes among ApoE4 carriers and non-carriers
§ To determine the effect of sample size, baseline characteristics, and discontinuation/drop-out rates on the outcomes of this study
§ To gauge the future potential and limitations of bapineuzumab in clinical practice
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Wyeth Pharmaceuticals |
WYE |
bapineuzumab |
|
Elan Corporation |
ELN |
bapineuzumab |
Inclusion Criteria and Panel Details:
|
Inclusion Criteria |
§ US-based § Training and board-certified in specialty § Two to 30 years of experience post-training § From academic medical centers, large private practice groups § Spend at least 60% of time in clinical practice § Manages a significant number of Alzheimer’s patients in practice § Not participated in a clinical trial related to bapineuzumab § Not holding a consulting position/employed by a Wyeth or Elan |
|
Discussion Dates |
July 11, 2008 through July 23, 2008. |
To purchase this report or request additional information, contact:
Print Abstract
For additional information on this study or to purchase, please call:
|
Discussion
Neuro |